

| L Number | Hits | Search Text  | DB  | Time stamp       |
|----------|------|--|---|------------------|
| 1        | 379  | ((436/500).CCLS.)  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 2        | 0    | ((436/500).CCLS.) same (TSH and receptor)  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 3        | 78   | ((436/500).CCLS.) and TSH  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 4        | 32   | ((436/500).CCLS.) and TSH) and receptor  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:25 |
| 5        | 10   | ((436/500).CCLS.) and TSH) and receptor) and urine                                   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:01 |
| 6        | 5    | ((436/500).CCLS.) and TSH) and receptor) and urine) and chromatography               | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:26 |
| 7        | 5    | ((436/500).CCLS.) and TSH) and receptor) and urine) and chromatography) and antibody | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:29 |
| 8        | 124  | disadvantages same RIA   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:29 |
| 9        | 13   | (disadvantages same RIA) same safety   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:44 |
| 10       | 0    | ((disadvantages same RIA) same safety) same TSH                                      | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:44 |

| L Number | Hits | Search Text  | DB  | Time stamp       |
|----------|------|--|---|------------------|
| 1        | 379  | (436/500).CCLS.  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 2        | 0    | ((436/500).CCLS.) same (TSH and receptor)  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 3        | 78   | ((436/500).CCLS.) and TSH  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:24 |
| 4        | 32   | ((436/500).CCLS.) and TSH) and receptor  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 16:25 |
| 5        | 10   | ((436/500).CCLS.) and TSH) and receptor) and urine                                     | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:01 |
| 6        | 5    | ((436/500).CCLS.) and TSH) and receptor) and urine) and chromatography                 | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:26 |
| 7        | 5    | ((436/500).CCLS.) and TSH) and receptor) and urine) and chromatography) and antibod\$3 | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:29 |
| 8        | 124  | disadvantages same RIA   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:29 |
| 9        | 13   | (disadvantages same RIA) same safety   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:44 |
| 10       | 0    | ((disadvantages same RIA) same safety) same TSH  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:45 |
| 11       | 80   | TSH same urine   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:45 |
| 12       | 67   | (TSH same urine) and antibod\$3  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:46 |
| 13       | 33   | ((TSH same urine) and antibod\$3) and receptor   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:46 |
| 15       | 2    | ((TSH same urine) and antibod\$3) and receptor) and label\$2) and hyperthyroid\$3      | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:48 |
| 14       | 20   | ((TSH same urine) and antibod\$3) and receptor) and label\$2                           | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:56 |
| 16       | 18   | ((TSH same urine) and antibod\$3) and receptor) and label\$2) and chromatography       | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2003/08/07 17:56 |